Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Ascendis Pharma ( (ASND) ).
On June 9, 2025, Ascendis Pharma announced interim results from its COACH Trial, which is the first clinical trial to evaluate the combination treatment of TransCon CNP and TransCon hGH in children with achondroplasia. The results showed significant improvements in growth and proportionality after 26 weeks, with a safety profile consistent with the monotherapies. The trial’s findings suggest that the combination treatment could enhance therapeutic outcomes for children with achondroplasia, potentially impacting Ascendis Pharma’s market position and offering new treatment avenues for stakeholders.
The most recent analyst rating on (ASND) stock is a Buy with a $165.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
Ascendis Pharma’s stock reflects a mix of strong revenue growth and innovative product development, offset by significant operational losses and financial instability. The technical analysis shows strong momentum, but valuation remains challenging with negative earnings. The earnings call further underscores the duality of growth potential and financial constraints.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical company based in Denmark, specializing in developing innovative therapies for rare diseases. The company’s primary focus is on creating prodrugs that offer sustained release of active ingredients, with key products including TransCon CNP and TransCon hGH, which are designed to treat conditions such as achondroplasia and pediatric growth hormone deficiency.
Average Trading Volume: 509,288
Technical Sentiment Signal: Buy
Current Market Cap: $10.45B
See more insights into ASND stock on TipRanks’ Stock Analysis page.